{"nctId":"NCT00274937","briefTitle":"Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer","startDateStruct":{"date":"2006-02-20","type":"ACTUAL"},"conditions":["Stage I Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7","Stage I Nasopharyngeal Undifferentiated Carcinoma AJCC v7","Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7","Stage II Nasopharyngeal Undifferentiated Carcinoma AJCC v7","Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7","Stage III Nasopharyngeal Undifferentiated Carcinoma AJCC v7","Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7","Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7"],"count":111,"armGroups":[{"label":"Stratum I (radiotherapy, chemoprotective agent)","type":"EXPERIMENTAL","interventionNames":["Drug: Amifostine","Other: Laboratory Biomarker Analysis","Radiation: Radiation Therapy"]},{"label":"Stratum II (chemotherapy, chemoprotective agent, radiotherapy)","type":"EXPERIMENTAL","interventionNames":["Drug: Amifostine","Drug: Cisplatin","Drug: Fluorouracil","Other: Laboratory Biomarker Analysis","Radiation: Radiation Therapy"]}],"interventions":[{"name":"Amifostine","otherNames":["Amifostine Trihydrate","Aminopropylaminoethylthiophosphoric Acid Trihydrate","APAETP","Cytofos","Ethiofos","Ethyol","Gammaphos","WR 2721","WR-2721","WR2721","YM-08310"]},{"name":"Cisplatin","otherNames":["Abiplatin","Blastolem","Briplatin","CDDP","Cis-diammine-dichloroplatinum","Cis-diamminedichloridoplatinum","Cis-diamminedichloro Platinum (II)","Cis-diamminedichloroplatinum","Cis-dichloroammine Platinum (II)","Cis-platinous Diamine Dichloride","Cis-platinum","Cis-platinum II","Cis-platinum II Diamine Dichloride","Cismaplat","Cisplatina","Cisplatinum","Cisplatyl","Citoplatino","Citosin","Cysplatyna","DDP","Lederplatin","Metaplatin","Neoplatin","Peyrone's Chloride","Peyrone's Salt","Placis","Plastistil","Platamine","Platiblastin","Platiblastin-S","Platinex","Platinol","Platinol- AQ","Platinol-AQ","Platinol-AQ VHA Plus","Platinoxan","Platinum","Platinum Diamminodichloride","Platiran","Platistin","Platosin"]},{"name":"Fluorouracil","otherNames":["5 Fluorouracil","5 Fluorouracilum","5 FU","5-Fluoro-2,4(1H, 3H)-pyrimidinedione","5-Fluorouracil","5-Fluracil","5-Fu","5FU","AccuSite","Carac","Fluoro Uracil","Fluouracil","Flurablastin","Fluracedyl","Fluracil","Fluril","Fluroblastin","Ribofluor","Ro 2-9757","Ro-2-9757"]},{"name":"Laboratory Biomarker Analysis","otherNames":[]},{"name":"Radiation Therapy","otherNames":["Cancer Radiotherapy","ENERGY_TYPE","Irradiate","Irradiated","Irradiation","Radiation","Radiation Therapy, NOS","Radiotherapeutics","Radiotherapy","RT","Therapy, Radiation"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histological diagnosis of nasopharyngeal carcinoma WHO type II or III\n\n  * Stage I-IV disease\n  * Newly diagnosed disease\n* Performance status\n\n  * Patients ≤ 16 years of age: Lansky 60-100%\n  * Patients \\> 16 years of age: Karnofsky 60-100%\n* Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min\n* Creatinine based on age/gender as follows:\n\n  * No greater than 0.4 mg/dL (for patients 1 month to \\< 6 months of age)\n  * No greater than 0.5 mg/dL (for patients 6 months to \\< 1 year of age)\n  * No greater than 0.6 mg/dL (for patients 1-2 years of age)\n  * No greater than 0.8 mg/dL (for patients \\< 6 years of age)\n  * No greater than 1.0mg/dL (for patients 6 to \\< 10 years of age)\n  * No greater than 1.2 mg/dL (for patients 10 to \\< 13 years of age)\n  * No greater than 1.4 mg/dL (for female patients 13 to ≥ 16 years of age)\n  * No greater than 1.5 mg/dL (for male patients 13 to \\< 16 years of age)\n  * No greater than 1.7 mg/dL (for male patients ≥ 16 years of age)\n* Bilirubin ≤ 1.5 times upper limit of normal (ULN) for age\n* AST or ALT \\< 2.5 times ULN for age\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No prior chemotherapy or radiotherapy to the nasopharynx or neck for the treatment of nasopharyngeal carcinoma","healthyVolunteers":false,"sex":"ALL","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Two Year Event-free Survival (EFS)","description":"The two-year event-free survival will be compared with a standard established from adult oncology data and the results of POG-9486. The two-year Kaplan-Meier estimate of event-free survival will be compared with 70% using a 1-sided test of size 0.05 using the asymptotic distribution of the complementary log-log distribution of the estimate.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.87","spread":null}]}]}]},{"type":"SECONDARY","title":"Predictive Value of Epstein-Barr Virus (EBV) DNA as Measured by Quantitative Detection at Enrollment on EFS 2 Years After Treatment","description":"Presence of EBV DNA in serum.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Prognostic Significance of EBV Viral Load","description":"Viral load in blood.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Predictive Value of the Detection of EBV DNA in the Peripheral Blood","description":"The prognostic value of the presence of EBV DNA will be assessed using the log-rank test, adjusted by initial stage of disease, if appropriate. The proposed analysis will take place at the analytic endpoint of the clinical trial.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Protective Effects of Amifostine Assessed Primarily by Sialometry","description":"Weight of stimulated saliva production in grams.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.97","spread":"5.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.39","spread":"4.71"}]}]}]},{"type":"SECONDARY","title":"Protective Effects of Amifostine Assessed Primarily by Sialometry: Weight of Unstimulated Saliva Production in Grams.","description":"Weight of unstimulated saliva production in grams.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.37","spread":"4.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.30","spread":"3.90"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":79,"n":111},"commonTop":["Hearing impaired","Fever","Vomiting","Tinnitus","White blood cell decreased"]}}}